Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of rituximab and golcadomide CC-99282 as a front-line, chemo-free treatment for older frail patients newly diagnosed with Diffuse Large B-Cell Non-Hodgkin Lymphoma DLBCL. This phase II, multicenter study focuses on patients aged 80 years or older who are considered frail based on a simplified geriatric assessment sGA and are not candidates for standard anthracycline-based chemotherapy. The study aims to assess efficacy and safety in this vulnerable population. Participants will receive an induction phase consisting of up to 6 cycles, each lasting 28 days. Cycle 1 includes rituximab intravenously on days 1, 8, and 15, golcadomide orally for days 1 to 14, and dexamethasone orally on days 1, 8, 15, and 22. Cycles 2 through 6 involve rituximab on day 1 and golcadomide orally for days 1 to 14. After induction, patients showing at least a partial response may undergo a consolidation phase starting within 6 to 8 weeks, receiving golcadomide orally for up to 6 more cycles. Involved site radiotherapy is permitted at the end of induction for PET-positive areas and may coincide with consolidation treatment. Throughout the study, patients will undergo response assessments after the 4th and 6th induction cycles and midway through consolidation to evaluate disease progression. Imaging such as PETCT or CT scans will be used for response and sarcopenia assessments. Quality of life will be measured at baseline and at multiple points during and after treatment. Follow-up monitoring will continue for 24 months, with visits every 3 months during the first year and every 6 months during the second year. Patients experiencing disease progression will be followed for survival until study completion. The primary outcome is progression-free survival at 24 months.
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.
Actively Recruiting
Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pumitamig combined with chemotherapy compared to bevacizumab combined with chemotherapy in adults with previously untreated, unresectable, or metastatic colorectal cancer. This phase 23 study aims to provide important information on treatment options for this type of advanced colorectal cancer. Participants will receive different combinations of study drugs, including pumitamig or bevacizumab, along with chemotherapy regimens such as FOLFOX, FOLFIRI, or CAPOX. The dosages are specified and given on designated days. The study uses a randomized, double-blind design to compare these treatments across multiple groups. During the study, participants will be closely monitored for tumor response, progression-free survival, and overall survival for up to five years. Evaluations include tumor measurements using RECIST criteria, safety assessments, and other clinical tests. This long-term follow-up helps researchers understand how well the treatments work and their effects over time.
Actively Recruiting
Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.
Actively Recruiting
Researchers are studying women who carry mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 to better understand their risk of developing cancer. This observational study aims to collect national data from women with these mutations, as current management strategies are not fully established. The study focuses on the Italian population, where an estimated 140,000 to 150,000 women carry these mutations, and many face a high lifetime risk of genetically linked tumors. Participants will be registered on a platform where their clinical data related to BRCA1 or BRCA2 mutations will be collected. The study does not involve treatment but gathers detailed information about mutation distribution, access to genetic evaluation, lifestyle risk factors, preventive strategies, and surgical risk reduction approaches such as salpingo-oophorectomy. Women in the study will provide data that researchers will analyze to understand mutation geography, related cancer types, and screening criteria. Data collection occurs over different time frames, including immediate and six-month intervals. The study continues through long-term observation to monitor outcomes and preventive efforts, with no active intervention applied to participants.
Actively Recruiting
Researchers are studying Classical Hodgkins Lymphoma cHL, a rare cancer of the immune system mostly affecting young adults. Despite advances in treatment, many patients experience relapse or resistant disease. The study aims to better understand the genetic and biological complexity of cHL using molecular profiling and advanced imaging techniques, to identify new markers that predict disease progression and improve personalized treatments. The study includes three groups patients who have completed treatment and entered follow-up, patients with confirmed relapse or disease progression, and a retrospective group of previously treated patients from medical archives. It combines genetic analysis, gene expression profiling, liquid biopsy of circulating DNA, and radiomic analysis of PET scans to capture tumor characteristics at diagnosis and during disease progression. Participants will provide tissue and blood samples, and undergo PET scan evaluations. Researchers will analyze genetic mutations, compare findings from tissue and liquid biopsies, and correlate these data with patient outcomes. The study will track participants over several years to assess how genetic and imaging markers relate to disease control, aiming to improve risk assessment and treatment decisions in cHL.
Actively Recruiting
Researchers are conducting an observational study to collect detailed data on primary ovarian leiomyosarcoma POLMS, a very rare and aggressive type of ovarian cancer. This study includes both past cases diagnosed since 1980 and newly identified cases, aiming to expand knowledge from a previously described group of 113 cases. The goal is to find patterns in diagnosis, treatment, and outcomes to help establish guidelines for managing this rare cancer. The study uses a national, multicenter design with retrospective and prospective data collection. Information is gathered through clinical case reviews and institutional archives, standardized via electronic case report forms on REDCap. The data collected covers patient demographics, tumor features, treatment details including surgery and therapies, recurrence, survival outcomes, and immunohistochemical markers. All information undergoes thorough validation to ensure consistency across centers. Participants provide data through medical records rather than active treatment. Researchers analyze tumor markers like CA-125 and Ki-67, treatment types, and patient outcomes including disease-free and overall survival. The main measurement is the relationship between treatment approaches and prognosis over a 3-year observation period. The study respects patient confidentiality by reporting aggregated results and spans adult female patients aged 18 to 99 years.
Actively Recruiting
This trial studies patients with early stage Follicular Lymphoma who have not received prior treatment. It is a phase III, multicenter, randomized clinical trial comparing two treatments to evaluate which approach better controls the disease. The study is open label, meaning both patients and researchers know the assigned treatments. The purpose is to assess progression-free survival and other outcomes over several years. Participants are randomly assigned to one of two groups one receives involved-site radiotherapy alone at a standard dose of 24 Gy, and the other receives the same radiotherapy followed by eight doses of Obinutuzumab given intravenously over approximately nine months. The Obinutuzumab doses start with four weekly infusions followed by four infusions every three weeks. This comparison aims to evaluate the potential benefit of adding Obinutuzumab to radiotherapy. During the study, participants undergo PETCT scans for staging and assessments, blood tests including PCR for molecular markers, bone marrow biopsies, and other laboratory tests to monitor response and safety. Researchers measure outcomes such as progression-free survival over 33 months, complete and overall response rates, and event-free survival over up to 45 months. Safety and molecular studies including liquid biopsies and genetic analyses are also performed. Participants are followed for several years to monitor disease status and side effects.
1-10 of 30
1